A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.
Bottom Line: Fulvestrant ("Faslodex") is a new oestrogen receptor antagonist that downregulates the oestrogen receptor and has no known agonist effect.Neither the 125 mg nor 250 mg doses of fulvestrant demonstrated oestrogenic effects on the endometrium over the initial 14-day assessment period.Fulvestrant was well tolerated and reduced the incidence of ethinyloestradiol-related side effects.
Affiliation: LCG Bioscience, Bourn Hall Clinic, Bourn, Cambridge, UK.Show MeSH
Related in: MedlinePlus
Affiliation: LCG Bioscience, Bourn Hall Clinic, Bourn, Cambridge, UK.